US Patent
US9186411 — Pharmaceutical composition
Formulation · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2030-08-11 · 4y remaining
Vulnerability score
56/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects a pharmaceutical composition or solid preparation containing a stabilized pharmaceutically active ingredient.
USPTO Abstract
The present invention provides a pharmaceutical composition or a solid preparation containing a stabilized pharmaceutically active ingredient and a stabilizing method thereof. According to the present invention, a pharmaceutical composition can be stabilized by containing a nonpeptidic pharmaceutically active ingredient having a primary or secondary amino group, an excipient and an acidic compound. In addition, a solid preparation containing a pharmaceutically active ingredient, titanium oxide, a plasticizer and a chain organic acid can enhance the stability of the pharmaceutically active ingredient during light irradiation.
Drugs covered by this patent
- Amoxil (amoxicillin) · Generic (originally Beecham/GSK)
- vonoprazan-fumarate (VONOPRAZAN FUMARATE)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.